← Back to Search

Continuous Glucose Monitor

Continuous Glucose Monitor (CGM) for Diabetes

N/A
Waitlist Available
Led By Adrian Dumitrascu, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up subject hospital discharge, up to approximately 3 months
Awards & highlights

Study Summary

This study is evaluating whether continuous glucose monitors are as accurate as point of care glucose monitors.

Eligible Conditions
  • Diabetes
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~subject hospital discharge, up to approximately 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and subject hospital discharge, up to approximately 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Absolute Relative Difference (MARD)
Secondary outcome measures
Blood Oxygen Level (SpO2)
CGM Accuracy in Lactic Acidosis.
CGM Recorded Hyperglycemia Episodes
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CGM UseExperimental Treatment1 Intervention
Determine CGM accuracy when compared with POC (point of care) glucometers.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuous Glucose Monitor (CGM)
2017
Completed Phase 3
~650

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,213 Previous Clinical Trials
3,766,991 Total Patients Enrolled
22 Trials studying Diabetes
6,803 Patients Enrolled for Diabetes
Adrian Dumitrascu, MDPrincipal InvestigatorMayo Clinic
3 Previous Clinical Trials
300 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))
Adrian G. Dumitrascu 2021. "CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04756141.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top